Ginkgo Bioworks vs Epic Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic biology platform for cell engineering; public company restructuring after SPAC overvaluation, shifting focus to government biosecurity contracts.
About
Ginkgo Bioworks is a synthetic biology platform company that provides cell programming services to the agricultural, pharmaceutical, food, and industrial chemicals industries, helping customers design and manufacture biological products using engineered microorganisms. Founded in 2008 by MIT researchers and headquartered in Boston, Ginkgo went public via SPAC merger in September 2021 at a $15 billion valuation — one of the largest biotech-related SPAC transactions ever.
Epic holds over 42% of U.S. acute care hospital EHR market share and is embedding AI across 150+ clinical workflows for 2026, while facing antitrust scrutiny.
About
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale electronic health record systems and reports that more than 305 million patients have a record in Epic, covering the majority of U.S. academic medical centers and large health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and Cleveland Clinic. Epic commands approximately 42% of U.S. acute care hospitals and nearly 55% of acute care hospital beds, making it the undisputed market leader in enterprise EHR.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.